Litcius/Paper detail

Structural basis of epitope recognition by anti-alpha-synuclein antibodies MJFR14-6-4-2

I. Lieknina, Lasse Reimer, Teodors Panteļejevs, Alons Lends, Kristaps Jaudzems, Aadil El-Turabi, Hjalte Gram, Anissa Hammi, Poul Henning Jensen, Kaspars Tārs

2024npj Parkinson s Disease12 citationsDOIOpen Access PDF

Abstract

Alpha-synuclein (α-syn) inclusions in the brain are hallmarks of so-called Lewy body diseases. Lewy bodies contain mainly aggregated α-syn together with some other proteins. Monomeric α-syn lacks a well-defined three-dimensional structure, but it can aggregate into oligomeric and fibrillar amyloid species, which can be detected using specific antibodies. Here we investigate the aggregate specificity of monoclonal MJFR14-6-4-2 antibodies. We conclude that partial masking of epitope in unstructured monomer in combination with a high local concentration of epitopes is the main reason for MJFR14-6-4-2 selectivity towards aggregates. Based on the structural insight, we produced mutant α-syn that when fibrillated is unable to bind MJFR14-6-4-2. Using these fibrils as a tool for seeding cellular α-syn aggregation, provides superior signal/noise ratio for detection of cellular α-syn aggregates by MJFR14-6-4-2. Our data provide a molecular level understanding of specific recognition of toxic amyloid oligomers, which is critical for the development of inhibitors against synucleinopathies.

Topics & Concepts

EpitopeSynucleinopathiesAlpha-synucleinMonoclonal antibodyChemistryAmyloid (mycology)ThioflavinLewy bodyAntibodyProtein aggregationMonomerDementia with Lewy bodiesBiophysicsBiochemistryCell biologyBiologyParkinson's diseaseImmunologyMedicineAlzheimer's diseaseDementiaPathologyDiseaseInorganic chemistryOrganic chemistryPolymerParkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatmentsNeurological disorders and treatments
Structural basis of epitope recognition by anti-alpha-synuclein antibodies MJFR14-6-4-2 | Litcius